Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on RegenXBio. The associated price target remains the same with $34.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen has given his Buy rating due to a combination of factors, primarily focusing on RegenXBio’s advanced manufacturing capabilities and commercial readiness. The company’s state-of-the-art manufacturing facility in Rockville, MD, is designed for scale and speed, featuring two independent bioreactor suites and comprehensive in-house capabilities. This setup allows RegenXBio to significantly reduce the drug development timeline, providing a strategic advantage over outsourcing models.
Additionally, the company’s proprietary NAVXpress platform ensures high-yield, high-purity AAV vector manufacturing, which is crucial for minimizing risks associated with gene therapy. With the capacity to support all three AAV-based programs, RegenXBio is well-prepared for commercial launches. The recent successful Pre-License Inspection for RGX-121 and the progress of other programs like RGX-202 and sura-vec further reinforce the company’s readiness and potential for growth, justifying the Buy rating and the $34 price target.
In another report released on November 14, Bank of America Securities also maintained a Buy rating on the stock with a $20.00 price target.